MAPT and Alzheimer disease: They have found that 170–172 decreased both intra- and extracellular Aβ levels and tau hyperphosphorylation via modulation of N-methyl-D-aspartate (NMDA) receptors that is possibly secondary to voltage-gated potassium (Kv) channel inhibition in an in vitro mouse model of AD [95].